Better Than Oil Stocks?
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.
Rita A.  Karachun net worth and biography

Rita Karachun Biography and Net Worth

Rita Karachun is the Senior Vice President Finance - Global Controller for Merck & Co., Inc. As Global Controller, Ms. Karachun is responsible for all accounting and reporting aspects for Merck. In this role, She has oversight responsibility for all accounting at Merck including developing accounting policies for Merck, the interpretation of those policies for specific transactions and the consolidation of Merck’s results.  Ms. Karachun also oversees Merck’s external reporting, the accounting for business development activity as well as managing the financial supply chain of intercompany sales transactions. Ms. Karachun joined Merck in 2007 as an Assistant Controller for Schering-Plough and continued as Assistant Controller for Merck after the merger between Schering-Plough and Merck in 2009. In these roles, She led the integration of Schering-Plough’s acquisition of OBS, a Netherlands-based company and also led the implementation of a global consolidation system. Before joining Schering-Plough, She worked at AT&T Corp. and it’s leasing subsidiary, AT&T Capital, for 16 years. Her last position with AT&T was Assistant Controller and Chief Accountant.  She held a variety of roles at AT&T of increasing responsibility, including investor relations manager and controller of corporate units. Prior to AT&T, she was a senior at Arthur Andersen & Co., Ms. Karachun is a certified public accountant and earned a B.S. degree in accounting from Fairleigh Dickinson University, graduating Summa Cum Laude.

What is Rita A. Karachun's net worth?

The estimated net worth of Rita A. Karachun is at least $4.75 million as of May 4th, 2023. Dr. Karachun owns 45,710 shares of Merck & Co., Inc. stock worth more than $4,752,012 as of September 28th. This net worth estimate does not reflect any other investments that Dr. Karachun may own. Learn More about Rita A. Karachun's net worth.

How do I contact Rita A. Karachun?

The corporate mailing address for Dr. Karachun and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Rita A. Karachun's contact information.

Has Rita A. Karachun been buying or selling shares of Merck & Co., Inc.?

Rita A. Karachun has not been actively trading shares of Merck & Co., Inc. within the last three months. Most recently, Rita A. Karachun sold 15,875 shares of the business's stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $117.53, for a transaction totalling $1,865,788.75. Following the completion of the sale, the vice president now directly owns 45,710 shares of the company's stock, valued at $5,372,296.30. Learn More on Rita A. Karachun's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, Merck & Co., Inc. insiders bought shares 3 times. They purchased a total of 150 shares worth more than $15,886.16. During the last year, insiders at the sold shares 24 times. They sold a total of 1,679,103 shares worth more than $177,166,367.00. The most recent insider tranaction occured on August, 14th when EVP Steven Mizell sold 4,250 shares worth more than $463,292.50. Insiders at Merck & Co., Inc. own 0.2% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 8/14/2023.

Rita A. Karachun Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2023Sell15,875$117.53$1,865,788.7545,710View SEC Filing Icon  
10/28/2022Sell31,997$100.34$3,210,578.9841,103View SEC Filing Icon  
11/3/2021Sell25,000$88.45$2,211,250.00View SEC Filing Icon  
2/14/2019Sell64,662$78.96$5,105,711.5253,327View SEC Filing Icon  
8/2/2018Sell5,000$65.01$325,050.00View SEC Filing Icon  
See Full Table

Rita A. Karachun Buying and Selling Activity at Merck & Co., Inc.

This chart shows Rita A Karachun's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $104.29
Low: $103.78
High: $104.97

50 Day Range

MA: $107.74
Low: $103.96
High: $111.34

2 Week Range

Now: $104.29
Low: $86.02
High: $119.65


4,758,794 shs

Average Volume

7,551,088 shs

Market Capitalization

$264.64 billion

P/E Ratio


Dividend Yield



Free Stock Analysis Report: Buy Sell Hold Predictions on Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free